tradingkey.logo

Pacific Biosciences of California Inc

PACB

1.320USD

-0.010-0.75%
Market hours ETQuotes delayed by 15 min
396.05MMarket Cap
LossP/E TTM

Pacific Biosciences of California Inc

1.320

-0.010-0.75%
More Details of Pacific Biosciences of California Inc Company
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Company Info
Ticker SymbolPACB
Company namePacific Biosciences of California Inc
IPO dateOct 27, 2010
CEOMr. Christian O. Henry
Number of employees575
Security typeOrdinary Share
Fiscal year-endOct 27
Address1305 O'brien Drive
CityMENLO PARK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94025
Phone16505218000
Websitehttps://www.pacb.com/
Ticker SymbolPACB
IPO dateOct 27, 2010
CEOMr. Christian O. Henry
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-17.96%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Mark Van Oene
Mr. Mark Van Oene
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jim R. Gibson
Mr. Jim R. Gibson
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
--
--
Ms. Kathy P. Ordonez
Ms. Kathy P. Ordonez
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-17.96%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumable revenue
20.10M
54.09%
Instrument revenue
11.02M
29.65%
Service And Other
6.04M
16.26%
By RegionUSD
Name
Revenue
Proportion
North America
16.30M
43.88%
Asia Pacific
11.61M
31.25%
Europe (including the Middle East and Africa)
9.24M
24.87%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumable revenue
20.10M
54.09%
Instrument revenue
11.02M
29.65%
Service And Other
6.04M
16.26%
Shareholding Stats
Updated: Fri, Jun 13
Updated: Fri, Jun 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.10%
Madrone Advisors, LLC
7.80%
SoftBank Group Corp
6.82%
BlackRock Institutional Trust Company, N.A.
6.81%
The Vanguard Group, Inc.
5.40%
Other
61.08%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.10%
Madrone Advisors, LLC
7.80%
SoftBank Group Corp
6.82%
BlackRock Institutional Trust Company, N.A.
6.81%
The Vanguard Group, Inc.
5.40%
Other
61.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.28%
Investment Advisor/Hedge Fund
11.14%
Holding Company
6.82%
Research Firm
2.18%
Hedge Fund
2.07%
Individual Investor
1.18%
Corporation
1.17%
Bank and Trust
0.50%
Pension Fund
0.26%
Other
28.40%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
600
215.28M
71.74%
-113.79M
2025Q1
629
227.30M
75.82%
-104.21M
2024Q4
625
258.31M
94.32%
-61.55M
2024Q3
618
231.32M
84.94%
-85.30M
2024Q2
629
240.26M
88.29%
-64.03M
2024Q1
637
265.38M
97.57%
-38.04M
2023Q4
643
276.71M
103.53%
-9.49M
2023Q3
631
258.82M
103.48%
-18.47M
2023Q2
639
248.61M
99.68%
-37.06M
2023Q1
649
249.45M
101.17%
-6.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
36.48M
12.16%
+434.08K
+1.20%
Mar 31, 2025
Madrone Advisors, LLC
23.39M
7.8%
--
--
Mar 31, 2025
SoftBank Group Corp
20.45M
6.82%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.44M
6.81%
-1.17M
-5.42%
Mar 31, 2025
The Vanguard Group, Inc.
16.21M
5.4%
+1.04M
+6.83%
Mar 31, 2025
Edmond de Rothschild Asset Management (France) S.A.
21.86M
7.28%
+508.70K
+2.38%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
9.57M
3.19%
-613.17K
-6.02%
Mar 31, 2025
State Street Global Advisors (US)
6.38M
2.13%
-47.38K
-0.74%
Mar 31, 2025
Geode Capital Management, L.L.C.
6.32M
2.11%
+54.32K
+0.87%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
4.89M
1.63%
-8.23K
-0.17%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
1.34%
iShares Genomics Immunology and Healthcare ETF
0.75%
Invesco NASDAQ Future Gen 200 ETF
0.58%
Global X Genomics & Biotechnology ETF
0.42%
ARK Innovation ETF
0.41%
WisdomTree BioRevolution Fund
0.31%
AXS Green Alpha ETF
0.27%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
View more
ARK Genomic Revolution ETF
Proportion1.34%
iShares Genomics Immunology and Healthcare ETF
Proportion0.75%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.58%
Global X Genomics & Biotechnology ETF
Proportion0.42%
ARK Innovation ETF
Proportion0.41%
WisdomTree BioRevolution Fund
Proportion0.31%
AXS Green Alpha ETF
Proportion0.27%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.04%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI